Asia Pacific Radiopharmaceuticals Market
حجم السوق بالمليار دولار أمريكي
CAGR :
% 
 فترة التنبؤ |
2024 –2031 |
 حجم السوق (السنة الأساسية) |
USD 1.76 Billion |
 حجم السوق (سنة التنبؤ) |
USD 2.73 Billion |
 CAGR |
% |
| Major Markets Players |
تجزئة سوق المواد الصيدلانية المشعة في منطقة آسيا والمحيط الهادئ، حسب النوع (المواد الصيدلانية المشعة التشخيصية والمواد الصيدلانية المشعة العلاجية)، التطبيق (التشخيصي والعلاجي)، نوع الدواء (الأدوية الجنيسة والعلامات التجارية)، المصدر (المفاعلات النووية، السيكلوترونات، وغيرها)، المستخدم النهائي (المستشفيات، مراكز التشخيص، معاهد أبحاث السرطان، مراكز الجراحة الخارجية، وغيرها) - اتجاهات الصناعة والتوقعات حتى عام 2031.
تحليل وحجم سوق المواد الصيدلانية المشعة في منطقة آسيا والمحيط الهادئ
إن سوق زراعة القرنية في منطقة آسيا والمحيط الهادئ مدفوع بعدة عوامل، بما في ذلك الانتشار المتزايد لأمراض القرنية، وتزايد عدد السكان المسنين، والتقدم في التكنولوجيا، وزيادة الطلب على الإجراءات الأقل توغلاً، والوعي المتزايد بزراعة القرنية، والمبادرات الحكومية والتمويل، والاعتماد المتزايد على العدسات الهجينة والتوريكية، والشعبية المتزايدة لإجراءات الربط المتقاطع، وتوسع المؤشرات لزراعة القرنية، والمنافسة التي تعزز الابتكار. تعمل هذه العوامل مجتمعة على دفع الطلب على زراعة القرنية، وخاصة في البلدان المتقدمة، حيث يسعى المرضى إلى علاجات فعالة لاضطرابات الرؤية والحالات مثل القرنية المخروطية، وخلل التنسج الفقاعي، واعتلال القرنية الفقاعي الكاذب.
تحلل شركة Data Bridge Market Research أن سوق المواد الصيدلانية المشعة في منطقة آسيا والمحيط الهادئ من المتوقع أن يصل إلى 2.73 مليار دولار أمريكي بحلول عام 2031 من 1.76 مليار دولار أمريكي في عام 2023، مع نمو بمعدل نمو سنوي مركب بنسبة 5.7٪ خلال الفترة المتوقعة من 2024 إلى 2031.
|
تقرير القياس |
تفاصيل |
|
فترة التنبؤ |
2024 إلى 2031 |
|
سنة الأساس |
2023 |
|
سنوات تاريخية |
2022 (قابلة للتخصيص 2016-2021) |
|
وحدات كمية |
الإيرادات بالمليار دولار أمريكي |
|
القطاعات المغطاة |
النوع (الأدوية الإشعاعية التشخيصية والأدوية الإشعاعية العلاجية)، التطبيق (التشخيصي والعلاجي)، نوع الدواء (الأدوية الجنيسة والأدوية ذات العلامات التجارية)، المصدر (المفاعلات النووية، السيكلوترونات، وغيرها)، المستخدم النهائي (المستشفيات، مراكز التشخيص، معاهد أبحاث السرطان، مراكز الجراحة الخارجية ، وغيرها) |
|
الدول المغطاة |
الصين واليابان وأستراليا وكوريا الجنوبية وسنغافورة والهند وإندونيسيا والفلبين وماليزيا وفيتنام وبقية دول آسيا والمحيط الهادئ |
|
الجهات الفاعلة في السوق المشمولة |
Cardinal Health، وAdvanced Accelerator Applications، وLantheus، وCurium، وGE HealthCare، وJubilant Radiopharma، (شركة Jubilant Pharma Company)، وAnsto، وEli Lilly And Company، وBayer AG، وSiemens Healthcare Gmbh، والصين، وlsotope & Radiation Corporation، وBracco، وNTP، وEckert & Ziegler، وEczacıbaşı-Monrol، وIBA Worldwide، وBWX Technologies. Inc، وIsotope JSC، وSterigenics US، LLC وغيرها. |
تعريف السوق
تحتوي المستحضرات الصيدلانية المشعة على مادة مشعة مرتبطة بمكون واحد أو أكثر، وهي مخصصة لتشخيص المرض أو تحديد مرحلة المرض أو مراقبة العلاج أو توفير العلاج. تشمل المستحضرات الصيدلانية المشعة مجموعة من العوامل المشعة المستخدمة إما للتدخلات التشخيصية أو العلاجية. المستحضرات الصيدلانية المشعة هي المستحضرات الصيدلانية التي تحتوي على نويدات مشعة. تتكون معظم المستحضرات الصيدلانية المشعة من مزيج من نويدات مشعة أو نويدات مشعة وجزيء أو عقار نشط بيولوجيًا يعمل كحامل ويحدد التوطين والتوزيع البيولوجي.
ديناميكيات سوق المواد الصيدلانية المشعة في منطقة آسيا والمحيط الهادئ
يتناول هذا القسم فهم محركات السوق والمزايا والفرص والقيود والتحديات. ويتم مناقشة كل هذا بالتفصيل على النحو التالي:
السائقين
الطلب المتزايد على المواد الصيدلانية المشعة في التشخيص والاستخدام السريري
أصبحت المستحضرات الصيدلانية المشعة ضرورية للمساعدة في تشخيص الأعضاء وعلاج الاضطرابات المرضية. يتم استخدامها في التصوير التشخيصي والعلاج الإشعاعي. لا تمتلك المستحضرات الصيدلانية المشعة التشخيصية أي تأثيرات دوائية ولا يُعتقد أيضًا أن تناولها مرتبط بآثار جانبية سريرية ذات صلة.
إن عدد المستحضرات الصيدلانية المشعة المستخدمة في المجال السريري يتزايد بسرعة، مما يسمح للمجتمع الطبي بالوصول بشكل أفضل إلى معلومات تفصيلية حول خصائص الأنواع المختلفة من الأورام. كما تكتسب النويدات المشعة أهمية من خلال توفير العلاج التلطيفي والعلاجي لعدد متزايد من الأمراض الخبيثة.
على سبيل المثال،
- في فبراير 2024، وفقًا للمقال الذي نشرته الوكالة الدولية للطاقة الذرية، تُستخدم المستحضرات الصيدلانية المشعة في التشخيص عن طريق إعطاء مركبات مشعة تنبعث منها فوتونات جاما، والتي تخترق الجسم ويتم اكتشافها بواسطة كاميرات خارجية لإنتاج صور للأنسجة أو الأعضاء المستهدفة. تساعد هذه الصور في اكتشاف الأورام وتقييم وظائف الأعضاء وتشخيص حالات مثل السرطان وأمراض القلب والأوعية الدموية. على عكس الأشعة السينية، غالبًا ما تكون هناك حاجة إلى فترة انتظار حتى تصل المستحضرات الصيدلانية المشعة إلى هدفها، مما يتيح التصوير الدقيق
الحاجة المتزايدة للمنتجات الصيدلانية في مختلف المجالات العلاجية
تشكل الحالات المتزايدة من الأمراض الجديدة في جميع أنحاء العالم مصدر قلق كبير لمقدمي الرعاية الصحية. تبذل شركات الأدوية والمستحضرات الصيدلانية الحيوية جهودًا يومية لمواجهة التحدي المرتبط بأمراض مختلفة. إن الاهتمام المتزايد من جانب اللاعبين في السوق الراغبين في توفير مجموعة واسعة من منتجات المستحضرات الصيدلانية المشعة لاستخدامها في تركيبة مختلفة يدفع نمو السوق.
The increasing disease prevalence which is related to age, population type, genetic inheritance, and chronic infectious disease spreading worldwide is the major factor owing to the increasing demand for radiopharmaceutical products. They have been described for the diagnosis of inflammatory chronic diseases and several peptides, receptor ligands and monoclonal antibodies have been radiolabeled which allows in-vivo visualization of inflammatory processes at a cellular and molecular level.
For instance,
- In February 2019, as per NCBI article, a number of recent developments suggest that radiopharmaceutical therapy is poised to emerge as an important and widely-recognized therapeutic modality which have the ability to deliver cytotoxic radiation to tumor cells without causing prohibitive normal tissue toxicity
Opportunity
The Rising Research and Development Expenditure of Radiopharmaceuticals
Technological advancements include enhancing the stability and strength of traditional pharmaceuticals. The biotechnology and pharma companies are continuously investing in research and development to offer innovative services for diagnostics as well as medications to the customers and enhance their market presence. Radiopharmaceuticals play a dynamic role in clinical development. While the diagnostic industry is in a constant state of fluctuation due to the implementation of new technologies in the market, the pharmaceutical and biotechnology industries continue to increase due to enhanced investment in radiopharmaceuticals companies along with mergers and acquisitions adoption of innovation in imaging technologies to support clinical trials for various diseases.
Restraint/Challenge
- Potential Risks Associated with Radiopharmaceuticals
Chronic inhalation exposure to uranium and radon in humans has been linked to respiratory effects, such as chronic lung disease, while radium exposure has resulted in acute leukopenia, anaemia, necrosis of the jaw, and other effects. The radioactive element radium looks like a calcium molecule which gets incorporated into areas of the body where bone turnover is high in amount such as areas of organs where cancer is growing, apart from this few procedural risks are also involved with the radiopharmaceuticals.
Recent Developments
• In October 2022, Cardinal Health was recognized by Forbes as one of America's Best Large Employers company 2022 through an independent survey taken by approximately 60,000 American employees working for U.S. companies. The company believes this will inspire them and will give motivation to their employees
- In December 2022, Novartis received the European Commission approval for Pluvicto as the first targeted radioligand therapy for treatment of prostate cancer. The company believes that this will help in advancing a broad portfolio of radioligand therapies to treat cancer
- In August 2024, Lantheus Holdings, Inc. (“Lantheus”), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the Mayo Clinic in Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002’s initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024
- In July 2024, ANSTO and the University of Wollongong have developed a Quad-MOSFET device for real-time quality control in boron neutron capture therapy. This innovative tool enhances precision by distinguishing neutron energy levels, improving cancer treatment safety and effectiveness
Asia-Pacific Radiopharmaceuticals Market Scope
The Asia-Pacific radiopharmaceuticals market is segmented into eight notable segments based on type, application, drug type, source, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
On the basis of type, the Asia-Pacific radiopharmaceuticals market is segmented into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals.
Application
- Diagnostic
- Therapeutic
On the basis of application, the Asia-Pacific radiopharmaceuticals market is segmented into diagnostic and therapeutic.
Drug Type
- Branded
- Generics
On the basis of drug type, the Asia-Pacific radiopharmaceuticals market is segmented into generics and branded.
Source
- Nuclear Reactors
- Cyclotrons
- Others
On the basis of source, the Asia-Pacific radiopharmaceuticals market is segmented into nuclear reactors, cyclotrons, and others.
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Institutes
- Ambulatory Surgical Centers
- Others
On the basis of end user, the Asia-Pacific radiopharmaceuticals market is segmented into hospitals, diagnostic centers, cancer research institutes, ambulatory surgical centers, and others.
Asia-Pacific Radiopharmaceuticals Market Regional Analysis/Insights
Asia-Pacific radiopharmaceuticals market is analyzed, and market size insights and trends are provided by based on type, application, drug type, source, and end user.
The countries covered in this market report are China, Japan, Australia, South Korea, Singapore, India, Indonesia, Philippines, Malaysia, Vietnam, and rest of Asia-Pacific.
China is expected to dominate in the Asia-Pacific market due to its large population, increasing healthcare spending, expanding pharmaceutical industry, growing consumer awareness, and demand for treatments, coupled with a developing healthcare infrastructure and a rising prevalence.
كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغيرات في تنظيم السوق التي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. نقاط البيانات مثل تحليل سلسلة القيمة المصب والمصب، والاتجاهات الفنية وتحليل قوى بورتر الخمس، ودراسات الحالة هي بعض المؤشرات المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في منطقة آسيا والمحيط الهادئ والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية، وتأثير التعريفات الجمركية المحلية وطرق التجارة أثناء تقديم تحليل توقعات لبيانات الدولة.
تحليل المنافسة وحصة سوق المواد الصيدلانية المشعة في منطقة آسيا والمحيط الهادئ
يوفر المشهد التنافسي لسوق الأدوية المشعة في منطقة آسيا والمحيط الهادئ تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور الإقليمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات على سوق الأدوية المشعة في منطقة آسيا والمحيط الهادئ.
بعض اللاعبين الرئيسيين العاملين في سوق الأدوية المشعة في منطقة آسيا والمحيط الهادئ هم Cardinal Health وAdvanced Accelerator Applications وLantheus وCurium وGE HealthCare وJubilant Radiopharma (شركة Jubilant Pharma Company) وAnsto وEli Lilly And Company وBayer AG وSiemens Healthcare Gmbh وChina وlsotope & Radiation Corporation وBracco وNTP وEckert & Ziegler وEczacıbaşı-Monrol وIBA Worldwide وBWX Technologies. Inc وIsotope JSC وSterigenics US وLLC وغيرها.
SKU-
احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم
- لوحة معلومات تحليل البيانات التفاعلية
- لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
- إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
- تحليل المنافسين باستخدام لوحة معلومات تفاعلية
- آخر الأخبار والتحديثات وتحليل الاتجاهات
- استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA PACIFIC RADIOPHARMACEUTICALS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET TESTING TYPE COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER FIVE FORCES
5 REGULATORY SCENARIO
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE
6.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS
6.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS
6.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS
6.3 OPPORTUNITIES
6.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS
6.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION
6.4 CHALLENGES
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS
6.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE
7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE
7.1 OVERVIEW
7.2 BRANDED
7.3 GENERICS
8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS
8.2.1 PET RADIOPHARMACEUTICALS
8.2.1.1 F-18
8.2.1.2 RU-82
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS
8.2.2 SPECT RADIOPHARMACEUTICALS
8.2.2.1 TECHNETIUM-99M
8.2.2.2 GALLIUM-67
8.2.2.3 IODINE-123
8.2.2.4 THALLIUM-201
8.2.2.5 OTHER SPECT ISOTOPES
8.3 THERAPEUTIC RADIOPHARMACEUTICALS
8.3.1 BRACHYTHERAPY ISOTOPES
8.3.1.1 IODINE-125
8.3.1.2 PALLADIUM-103
8.3.1.3 CESIUM-131
8.3.1.4 IRIDIUM-192
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES
8.3.2 BETA EMITTERS
8.3.2.1 IODINE-131
8.3.2.2 LUTHETIUM-177
8.3.2.3 SAMARIUM-153
8.3.2.4 YTTRIUM-90
8.3.2.5 RHENIUM-186
8.3.2.6 OTHER BETA EMITTERS
8.3.3 ALPHA EMITTERS
8.3.3.1 RA-223
8.3.3.2 OTHERS
9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DIAGNOSTIC
9.2.1 ONCOLOGY
9.2.2 CARDIOLOGY
9.2.3 NEUROLOGY
9.2.4 BONE SCANS
9.2.5 THYROID APPLICATIONS
9.2.6 PULMONARY SCANS
9.2.7 OTHERS
9.3 THERAPEUTIC
9.3.1 THYROID INDICATIONS
9.3.2 BONE METASTASIS
9.3.3 LYMPHOMA
9.3.4 ENDOCRINE TUMORS
9.3.5 OTHER INDICATIONS
10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE
10.1 OVERVIEW
10.2 NUCLEAR REACTORS
10.3 CYCLOTRONS
10.4 OTHERS
11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC
11.2.2 PRIVATE
11.2.2.1 DIAGNOSTIC CENTERS
11.2.2.2 CANCER RESEARCH INSTITUTES
11.2.2.3 AMBULATORY SURGICAL CENTERS
11.2.2.4 OTHERS
12 APAC RADIOPHARMACEUTICALS MARKET, BY COUNTRY
12.1 ASIA-PACIFIC
13 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 CARDINAL HEALTH
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENT
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENT
15.3 LANTHEUS
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 CURIUM
15.4.1 COMPANY SNAPSHOT
15.4.2 PRODUCT PORTFOLIO
15.4.3 RECENT DEVELOPMENT
15.5 GE HEALTHCARE
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 PRODUCT PORTFOLIO
15.5.4 RECENT DEVELOPMENT
15.6 ANSTO
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT UPDATES
15.7 BAYER AG
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 BRACCO
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BWX TECHNOLOGIES. INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 CHINA ISOTOPE & RADIATION CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 ELI LILLY AND COMPANY
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 ECKERT & ZIEGLER
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 GLOBAL MEDICAL SOLUTIONS
15.13.1 COMPANY SNAPSHOT
15.13.2 PRODUCT PORTFOLIO
15.13.3 RECENT DEVELOPMENT
15.14 ECZACIBAŞI-MONROL
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 IBA WORLDWIDE
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 ISOTOPE JSC
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.17 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 MALLINCKRODT PHARMACEUTICALS
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT UPDATES
15.19 NTP
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 SIEMENS HEALTHCARE GMBH
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENT
15.21 STERIGENICS U.S., LLC – A SOTERA HEALTH COMPANY
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 3 ASIA-PACIFIC DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 5 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 6 ASIA-PACIFIC PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 7 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 9 ASIA-PACIFIC SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 10 ASIA-PACIFIC THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 11 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 13 ASIA-PACIFIC BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 14 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 15 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 16 ASIA-PACIFIC BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 17 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 18 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 19 ASIA-PACIFIC ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 21 ASIA-PACIFIC DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 22 ASIA-PACIFIC THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 25 ASIA-PACIFIC HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 27 CHINA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 28 CHINA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 29 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 30 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 31 CHINA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 32 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 33 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 34 CHINA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 35 CHINA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 36 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 37 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 38 100
TABLE 39 CHINA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 40 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 41 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 42 CHINA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 43 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 44 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 45 CHINA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 46 CHINA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 47 CHINA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 CHINA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 CHINA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 50 CHINA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 51 CHINA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 52 CHINA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 AUSTRALIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 55 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 56 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 57 AUSTRALIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 58 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 60 AUSTRALIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 61 AUSTRALIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 64 AUSTRALIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 65 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 67 AUSTRALIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 68 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 70 AUSTRALIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 71 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 72 AUSTRALIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 73 AUSTRALIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 75 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 76 AUSTRALIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 77 AUSTRALIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 78 JAPAN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 JAPAN DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 82 JAPAN PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 83 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 85 JAPAN SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 86 JAPAN THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 89 JAPAN BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 90 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 92 JAPAN BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 93 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 94 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 95 JAPAN ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 96 JAPAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 97 JAPAN DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 JAPAN THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 JAPAN RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 100 JAPAN RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 101 JAPAN RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 102 JAPAN HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 SOUTH KOREA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 106 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 107 SOUTH KOREA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 108 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 110 SOUTH KOREA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 111 SOUTH KOREA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 112 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 113 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 114 SOUTH KOREA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 115 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 117 SOUTH KOREA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 118 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 119 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 120 SOUTH KOREA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 121 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 122 SOUTH KOREA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 SOUTH KOREA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 125 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 126 SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 127 SOUTH KOREA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 128 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 129 SINGAPORE DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 130 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 132 SINGAPORE PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 133 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 135 SINGAPORE SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 136 SINGAPORE THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 138 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 139 SINGAPORE BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 140 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 141 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 142 SINGAPORE BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 143 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 144 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 145 SINGAPORE ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 146 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 147 SINGAPORE DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 SINGAPORE THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 149 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 150 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 151 SINGAPORE RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 SINGAPORE HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 153 INDIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 154 INDIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 155 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 156 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 157 INDIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 158 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 159 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 160 INDIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 161 INDIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 162 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 163 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 164 INDIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 165 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 167 INDIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 168 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 169 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 170 INDIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 171 INDIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 172 INDIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 INDIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 INDIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 175 INDIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 176 INDIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 INDIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 178 INDONESIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 179 INDONESIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 180 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 182 INDONESIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 183 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 184 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 185 INDONESIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 186 INDONESIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 187 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 188 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 189 INDONESIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 190 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 191 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 192 INDONESIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 193 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 194 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 195 INDONESIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 196 INDONESIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 197 INDONESIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 INDONESIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 199 INDONESIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 200 INDONESIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 201 INDONESIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 202 INDONESIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 203 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 204 PHILIPPINES DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 207 PHILIPPINES PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 208 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 209 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 210 PHILIPPINES SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 211 PHILIPPINES THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 212 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 213 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 214 PHILIPPINES BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 215 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 216 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 217 PHILIPPINES BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 218 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 220 PHILIPPINES ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 221 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 222 PHILIPPINES DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 224 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 225 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 227 PHILIPPINES HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 228 THAILAND RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 THAILAND DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 231 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 232 THAILAND PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 233 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 234 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 235 THAILAND SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 236 THAILAND THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 239 THAILAND BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 240 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 241 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 242 THAILAND BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 243 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 244 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 245 THAILAND ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 246 THAILAND RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 247 THAILAND DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 THAILAND THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 249 THAILAND RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 250 THAILAND RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 251 THAILAND RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 THAILAND HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 253 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 254 MALAYSIA DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 257 MALAYSIA PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 258 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 259 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 260 MALAYSIA SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 261 MALAYSIA THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 262 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 264 MALAYSIA BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 265 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 266 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 267 MALAYSIA BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 268 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 269 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 270 MALAYSIA ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 271 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 272 MALAYSIA DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 MALAYSIA THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 274 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 275 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 276 MALAYSIA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 277 MALAYSIA HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 278 VIETNAM RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 279 VIETNAM DIAGNOSTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 280 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 282 VIETNAM PET RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 283 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 284 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 285 VIETNAM SPECT RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 286 VIETNAM THERAPEUTIC RADIOPHARMACEUTICALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 287 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 288 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 289 VIETNAM BRACHYTHERAPY ISOTOPES IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 290 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 291 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 292 VIETNAM BETA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 293 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 294 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (VOLUME IN MBQ)
TABLE 295 VIETNAM ALPHA EMITTERS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (ASP PER MBQ)
TABLE 296 VIETNAM RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 297 VIETNAM DIAGNOSTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 298 VIETNAM THERAPEUTIC IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 299 VIETNAM RADIOPHARMACEUTICALS MARKET, BY DRUG TYPE, 2022-2031 (USD MILLION)
TABLE 300 VIETNAM RADIOPHARMACEUTICALS MARKET, BY SOURCE, 2022-2031 (USD MILLION)
TABLE 301 VIETNAM RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 302 VIETNAM HOSPITALS IN RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 303 REST OF ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 ASIA PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: MARKET TESTING TYPE COVERAGE GRID
FIGURE 9 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET:
FIGURE 12 EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 THE RISING PREVALENCE OF CHRONIC DISEASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD
FIGURE 15 THE TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2023
FIGURE 18 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, 2024-2031 (USD MILLION)
FIGURE 19 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, CAGR (2024-2031)
FIGURE 20 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2023
FIGURE 22 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 23 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 24 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2023
FIGURE 26 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 27 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 28 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2023
FIGURE 30 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, 2024-2031 (USD MILLION)
FIGURE 31 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, CAGR (2024-2031)
FIGURE 32 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2023
FIGURE 34 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 35 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2024-2031)
FIGURE 36 ASIA-PACIFIC RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 APAC RADIOPHARMACEUTICALS MARKET BY SNAPSHOT
FIGURE 38 AISA-PACIFIC RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2023 (%)
منهجية البحث
يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.
منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.
التخصيص متاح
تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.
